Cargando…

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)

BACKGROUND: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrein, Melissa, Li, Xinmin S., Walter, Joan, Wang, Zeneng, Zimmermann, Tobias, Strebel, Ivo, Honegger, Ursina, Leu, Kathrin, Schäfer, Ibrahim, Twerenbold, Raphael, Puelacher, Christian, Glarner, Noemi, Nestelberger, Thomas, Koechlin, Luca, Ceresa, Benjamin, Haaf, Philip, Bakula, Adam, Zellweger, Michael, Hazen, Stanley L., Mueller, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151506/
https://www.ncbi.nlm.nih.gov/pubmed/35220448
http://dx.doi.org/10.1007/s00392-022-01992-6
_version_ 1784717497333710848
author Amrein, Melissa
Li, Xinmin S.
Walter, Joan
Wang, Zeneng
Zimmermann, Tobias
Strebel, Ivo
Honegger, Ursina
Leu, Kathrin
Schäfer, Ibrahim
Twerenbold, Raphael
Puelacher, Christian
Glarner, Noemi
Nestelberger, Thomas
Koechlin, Luca
Ceresa, Benjamin
Haaf, Philip
Bakula, Adam
Zellweger, Michael
Hazen, Stanley L.
Mueller, Christian
author_facet Amrein, Melissa
Li, Xinmin S.
Walter, Joan
Wang, Zeneng
Zimmermann, Tobias
Strebel, Ivo
Honegger, Ursina
Leu, Kathrin
Schäfer, Ibrahim
Twerenbold, Raphael
Puelacher, Christian
Glarner, Noemi
Nestelberger, Thomas
Koechlin, Luca
Ceresa, Benjamin
Haaf, Philip
Bakula, Adam
Zellweger, Michael
Hazen, Stanley L.
Mueller, Christian
author_sort Amrein, Melissa
collection PubMed
description BACKGROUND: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated. METHODS: Among 1726 patients with suspected fCAD serum TMAO, and its precursors betaine, choline and carnitine, were quantified using liquid chromatography tandem mass spectrometry. Diagnosis of fCAD was performed by myocardial perfusion single photon emission tomography (MPI-SPECT) and coronary angiography blinded to marker concentrations. Incident all-cause death, cardiovascular death (CVD) and myocardial infarction (MI) were assessed during 5-years follow-up. RESULTS: Concentrations of TMAO, betaine, choline and carnitine were significantly higher in patients with fCAD versus those without (TMAO 5.33 μM vs 4.66 μM, p < 0.001); however, diagnostic accuracy was low (TMAO area under the receiver operating curve [AUC]: 0.56, 95% CI [0.53–0.59], p < 0.001). In prognostic analyses, TMAO, choline and carnitine above the median were associated with significantly (p < 0.001 for all) higher cumulative events for death and CVD during 5-years follow-up. TMAO remained a significant predictor for death and CVD even in full models adjusted for renal function (HR = 1.58 (1.16, 2.14), p = 0.003; HR = 1.66 [1.07, 2.59], p = 0.025). Prognostic discriminative accuracy for TMAO was good and robust for death and CVD (2-years AUC for CVD 0.73, 95% CI [0.65–0.80]). CONCLUSION: TMAO and its precursors, betaine, choline and carnitine were significantly associated with fCAD, but with limited diagnostic value. TMAO was a strong predictor for incident death and CVD in patients with suspected fCAD. CLINICAL TRIAL REGISTRATION: NCT01838148. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-01992-6.
format Online
Article
Text
id pubmed-9151506
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91515062022-06-01 Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD) Amrein, Melissa Li, Xinmin S. Walter, Joan Wang, Zeneng Zimmermann, Tobias Strebel, Ivo Honegger, Ursina Leu, Kathrin Schäfer, Ibrahim Twerenbold, Raphael Puelacher, Christian Glarner, Noemi Nestelberger, Thomas Koechlin, Luca Ceresa, Benjamin Haaf, Philip Bakula, Adam Zellweger, Michael Hazen, Stanley L. Mueller, Christian Clin Res Cardiol Original Paper BACKGROUND: Trimethylamine N-oxide (TMAO) has been associated with cardiovascular outcomes. However, the diagnostic value of TMAO and its precursors have not been assessed for functionally relevant coronary artery disease (fCAD) and its prognostic potential in this setting needs to be evaluated. METHODS: Among 1726 patients with suspected fCAD serum TMAO, and its precursors betaine, choline and carnitine, were quantified using liquid chromatography tandem mass spectrometry. Diagnosis of fCAD was performed by myocardial perfusion single photon emission tomography (MPI-SPECT) and coronary angiography blinded to marker concentrations. Incident all-cause death, cardiovascular death (CVD) and myocardial infarction (MI) were assessed during 5-years follow-up. RESULTS: Concentrations of TMAO, betaine, choline and carnitine were significantly higher in patients with fCAD versus those without (TMAO 5.33 μM vs 4.66 μM, p < 0.001); however, diagnostic accuracy was low (TMAO area under the receiver operating curve [AUC]: 0.56, 95% CI [0.53–0.59], p < 0.001). In prognostic analyses, TMAO, choline and carnitine above the median were associated with significantly (p < 0.001 for all) higher cumulative events for death and CVD during 5-years follow-up. TMAO remained a significant predictor for death and CVD even in full models adjusted for renal function (HR = 1.58 (1.16, 2.14), p = 0.003; HR = 1.66 [1.07, 2.59], p = 0.025). Prognostic discriminative accuracy for TMAO was good and robust for death and CVD (2-years AUC for CVD 0.73, 95% CI [0.65–0.80]). CONCLUSION: TMAO and its precursors, betaine, choline and carnitine were significantly associated with fCAD, but with limited diagnostic value. TMAO was a strong predictor for incident death and CVD in patients with suspected fCAD. CLINICAL TRIAL REGISTRATION: NCT01838148. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-01992-6. Springer Berlin Heidelberg 2022-02-26 2022 /pmc/articles/PMC9151506/ /pubmed/35220448 http://dx.doi.org/10.1007/s00392-022-01992-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Amrein, Melissa
Li, Xinmin S.
Walter, Joan
Wang, Zeneng
Zimmermann, Tobias
Strebel, Ivo
Honegger, Ursina
Leu, Kathrin
Schäfer, Ibrahim
Twerenbold, Raphael
Puelacher, Christian
Glarner, Noemi
Nestelberger, Thomas
Koechlin, Luca
Ceresa, Benjamin
Haaf, Philip
Bakula, Adam
Zellweger, Michael
Hazen, Stanley L.
Mueller, Christian
Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
title Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
title_full Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
title_fullStr Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
title_full_unstemmed Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
title_short Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)
title_sort gut microbiota-dependent metabolite trimethylamine n-oxide (tmao) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fcad)
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151506/
https://www.ncbi.nlm.nih.gov/pubmed/35220448
http://dx.doi.org/10.1007/s00392-022-01992-6
work_keys_str_mv AT amreinmelissa gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT lixinmins gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT walterjoan gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT wangzeneng gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT zimmermanntobias gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT strebelivo gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT honeggerursina gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT leukathrin gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT schaferibrahim gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT twerenboldraphael gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT puelacherchristian gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT glarnernoemi gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT nestelbergerthomas gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT koechlinluca gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT ceresabenjamin gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT haafphilip gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT bakulaadam gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT zellwegermichael gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT hazenstanleyl gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad
AT muellerchristian gutmicrobiotadependentmetabolitetrimethylaminenoxidetmaoandcardiovascularriskinpatientswithsuspectedfunctionallyrelevantcoronaryarterydiseasefcad